- Home
- FENC vs CRGX Comparison
FENC vs CRGX Comparison
Compare FENC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- CRGX
- Stock Information
- Founded
- FENC 1996
- CRGX 2021
- Country
- FENC United States
- CRGX United States
- Employees
- FENC N/A
- CRGX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- CRGX
- Sector
- FENC Health Care
- CRGX
- Exchange
- FENC Nasdaq
- CRGX Nasdaq
- Market Cap
- FENC 229.8M
- CRGX 190.0M
- IPO Year
- FENC 2001
- CRGX 2023
- Fundamental
- Price
- FENC $7.76
- CRGX $4.27
- Analyst Decision
- FENC Strong Buy
- CRGX Hold
- Analyst Count
- FENC 2
- CRGX 7
- Target Price
- FENC $13.00
- CRGX $4.67
- AVG Volume (30 Days)
- FENC 86.3K
- CRGX 647.1K
- Earning Date
- FENC 08-12-2025
- CRGX 08-11-2025
- Dividend Yield
- FENC N/A
- CRGX N/A
- EPS Growth
- FENC N/A
- CRGX N/A
- EPS
- FENC N/A
- CRGX N/A
- Revenue
- FENC $30,912,000.00
- CRGX N/A
- Revenue This Year
- FENC $0.85
- CRGX $58.18
- Revenue Next Year
- FENC $55.16
- CRGX N/A
- P/E Ratio
- FENC N/A
- CRGX N/A
- Revenue Growth
- FENC N/A
- CRGX N/A
- 52 Week Low
- FENC $3.96
- CRGX $3.00
- 52 Week High
- FENC $8.72
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FENC 51.69
- CRGX 45.02
- Support Level
- FENC $7.53
- CRGX $4.33
- Resistance Level
- FENC $8.19
- CRGX $4.48
- Average True Range (ATR)
- FENC 0.47
- CRGX 0.19
- MACD
- FENC -0.12
- CRGX -0.02
- Stochastic Oscillator
- FENC 19.67
- CRGX 21.14
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.